Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.54 |
| ▸ | CCR2 | P41597 | 3/20 | 0.52 |
| ▸ | F10 | P00742 | 2/20 | 0.51 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6780431 | 0.90 | ABCB11 (0.51) | PPARGCCR2F10NOD2NOD1 | |
| SCHEMBL12930106 | 0.89 | NOD2 (0.58) | PPARGCCR2F10NOD2NOD1 | |
| SCHEMBL4655319 | 0.88 | CCR2 (0.67) | PPARGCCR2 | |
| SCHEMBL1054163 | 0.87 | NOD2 (0.55) | PPARGCCR2F10NOD2NOD1 | |
| SCHEMBL3571653 | 0.87 | NOD2 (0.67) | PPARGF10NOD2NOD1 | |
| SCHEMBL925921 | 0.86 | F10 (0.51) | PPARGCCR2F10NOD2NOD1 | |
| SCHEMBL9622481 | 0.85 | NOD2 (0.64) | CCR2F10NOD2NOD1MAPT | |
| SCHEMBL3979074 | 0.84 | F10 (0.52) | PPARGCCR2F10NOD2NOD1 | |
| SCHEMBL15304629 | 0.84 | F10 (0.48) | PPARGCCR2F10NOD2NOD1 | |
| SCHEMBL12930102 | 0.83 | NOD2 (0.58) | PPARGCCR2F10NOD2NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781477-B2 | Therapeutic use of N-(1H-Indolyl)-1H-indole-2-carboxamide derivatives | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| US-20090286846-A1 | Therapeutic use of N-(1H-Indolyl)-1H-indole-2-carboxamide derivatives | SANOFI-AVENTIS (FR) | 2009-11-19 | — | — | US | disclosed |
| US-7582671-B2 | Therapeutic use of N-(1H-indolyl)-1H-indole-2-carboxamide derivatives | SANOFI-AVENTIS (FR) | 2009-09-01 | — | — | US | disclosed |
| US-20080227843-A1 | THERAPEUTIC USE OF N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | US | disclosed |
| US-7384969-B2 | N-(1H-indolyl)-1H-indole-2-carboxamide derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2008-06-10 | — | — | US | disclosed |
| US-20070149602-A1 | N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149602-A1 | N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | IDO1, IDO2, NPY5R | PPARG 2147/4885CCR2 631/4885F10 1655/4885 |
| US-20080227843-A1 | THERAPEUTIC USE OF N-(1H-INDOLYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES | NPY5R, TPH2, TPH1 | PPARG 1964/4885CCR2 1264/4885F10 1905/4885 |
| US-20090286846-A1 | Therapeutic use of N-(1H-Indolyl)-1H-indole-2-carboxamide derivatives | NPY5R, TPH2, TPH1 | PPARG 1964/4885CCR2 1264/4885F10 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.